Immunotherapy combination offers new hope for women with early stage triple negative breast cancer – News-Medical.net
Fox News |
Immunotherapy combination offers new hope for women with early stage triple negative breast cancer
News-Medical.net A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the … As scientists train the immune system to fight cancer, others look to combat costs |
